Compare RYAM & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAM | BIOA |
|---|---|---|
| Founded | 1926 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.1M | 443.9M |
| IPO Year | N/A | 2024 |
| Metric | RYAM | BIOA |
|---|---|---|
| Price | $5.84 | $14.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 544.0K | 474.9K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,471,356,000.00 | $5,917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.35 | $2.88 |
| 52 Week High | $8.56 | $14.46 |
| Indicator | RYAM | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 77.95 |
| Support Level | $5.59 | $12.93 |
| Resistance Level | $5.92 | $13.68 |
| Average True Range (ATR) | 0.22 | 0.83 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 27.93 | 91.01 |
Rayonier Advanced Materials Inc is engaged in the production of cellulose specialties, a natural polymer used in the manufacturing of various specialty chemical products, including liquid crystal displays, filters, textiles and performance additives for pharmaceutical, food and other industrial applications. The company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, and High-Yield Pulp. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of its revenue from the United States.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.